The aim was to identify the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), assess the PK properties, and evaluate preliminary anti-tumor activities in women with advanced or metastatic ER + , HER2 − breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.